World EPA Congress Presentation:
"How AI And Machine Learning Can Improve Patient Access To Orphan Drugs"

11 May 2022

Vidya Breeveld-Dwarkasing Presentations

May 11, 2022 Vidya Breeveld-Dwarkasing

On March 22 2022 I held this thought-provoking presentation about the use of modern information technologies to aid patient access to orphan drugs at the World EPA congress in Amsterdam.

My conclusion: These technologies could be valuable instruments that help to provide solutions to fill the data gaps in health technology assessments and guide policy decisions. However, since there are many actors involved, to improve patient access to orphan drugs an ecosystem innovation is needed. Unless this is addressed, these modern technologies will not provide solutions that benefit patient access.

World EPA Congress Presentation By Vidya Dwarkasing

World EPA Congress Presentation in Amsterdam - Vidya Dwarkasing

The Orphan Drug Market Access Dilemma - World EPA Congress

World EPA Congress Presentation in Amsterdam By Vidya Dwarkasing

Inequity in patient access Presentation In World EPA Congress

The healthcare system focus (World EPA Congress Presentation)

RWE about a drug's efficacy, guiding reimbursement and clinical practices:

Complexity and Policymaking (World EPA Congress Vidya Dwarkasing)

European payers demand RWE to support HTA and reimbursement decisions

Is the ecosystem ready to embrace this approach?

How can AI & Machine learning aid national reimbursement decisions and improve patient access to orphan medicines?

Information technologies, World EPA Congress Presentation

Vidya Breeveld-Dwarkasing

Vidya started working as a pricing & reimbursement manager in Pharma in 2010, after a short one-year career as a regulatory affairs manager. Before that, as a trained veterinarian she had an academic career at the Utrecht University, Faculty of veterinary medicine. There she acquired a Ph.D. in Biomedical science while teaching obstetrics and gynecology in farm animals at the herd health department. During her years in Novartis, Abbvie, Sanofi Pasteur-MSD and most recent Sanofi, she acquired extensive experience in public affairs, pricing & market access, team management, incorporate initiatives, training & development, and stakeholder engagement. She is formally qualified to teach at the university level. That also helps her to deploy different training methodologies depending on the team composition and training goals. She is adept at developing access strategies and creating cross-functional alignment to successfully execute reimbursement procedures and product launches in complex circumstances. View all posts by Vidya Breeveld-Dwarkasing

World EPA Congress Presentation: "How AI And Machine Learning Can Improve Patient Access To Orphan Drugs"

Vidya Breeveld-Dwarkasing

World EPA Congress Presentation:
"How AI And Machine Learning Can Improve Patient Access To Orphan Drugs"